Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Geriatrics | Gynecology | Neurology | Nursing | Pharmacy | Psychiatry | Journal

Back to Journal Articles

Timing of Hormone Therapy Use Impacts Alzheimer’s Risk

Last Updated: October 25, 2012.

 

Women who start hormone therapy within five years of menopause have 30 percent reduced risk

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Use of hormone therapy within five years of menopause is associated with a reduction in the risk of Alzheimer's disease, according to a study published online Oct. 24 in Neurology.

THURSDAY, Oct. 25 (HealthDay News) -- Use of hormone therapy (HT) within five years of menopause is associated with a reduction in the risk of Alzheimer's disease (AD), according to a study published online Oct. 24 in Neurology.

Huibo Shao, from Weill Cornell Medical College in New York City, and colleagues examined whether the timing or type of HT impacts its association with AD. A cohort of 1,768 women from the Cache County Study who provided a detailed history of age at menopause and use of HT were followed between 1995 and 2006. One hundred seventy-six women developed incident AD during this period.

The researchers found that use of any type of HT within five years of menopause was associated with a significant 30 percent reduction in the risk of AD, particularly if HT was used for 10 years or more. There was no reduction in AD risk seen for women who initiated HT five years or more after menopause. Women who began "opposed" estrogen-progestin compounds within three years preceding the Cache County Study baseline had an increased risk of AD (adjusted hazard ratio, 1.93; 95 percent confidence interval, 0.94 to 3.96), which was similar to that reported in randomized trial participants assigned to opposed HT.

"Association of HT use and risk of AD may depend on timing of use. Although possibly beneficial if taken during a critical window near menopause, HT (especially opposed compounds) initiated in later life may be associated with increased risk," the authors write. "The relation of AD risk to timing and type of HT deserves further study."

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Poor Physical Performance Linked to Dementia in Over-90s Next: Negative Pigment Network Able to Distinguish Melanoma

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.